Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 2, 2015
Purpose: The filing serves to submit unredacted versions of Exhibit 10.1 (Confidential Settlement Agreement and Mutual Release) and Exhibit 10.2 (Exclusive License Agreement for Tuschl II United States Patents and Patent Applications). These documents were originally filed as exhibits to the Company's Form 10-Q for the quarter ended March 31, 2011. The refiling is necessary because the term for confidential treatment of the previously redacted information has expired.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly administrative regarding the disclosure of historical legal agreements.
Material Changes
There are no material changes to the Company's financial condition or operations reported in this document. The only change is the public availability of previously redacted terms within two agreements dated March 14, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It solely addresses the procedural requirement to disclose expired confidential information.
Key Facts for Investor Verification
- The filing is a procedural update to disclose unredacted versions of agreements from 2011, not a report on current 2015 performance.
- Exhibit 10.1 involves a settlement and release between Alnylam, Max-Planck-Gesellschaft, Max-Planck-Innovation, Whitehead Institute, MIT, and the University of Massachusetts.
- Exhibit 10.2 is an exclusive license agreement for Tuschl II patents between Alnylam and the University of Massachusetts.
- No new financial data or operational updates are provided in this specific 8-K.